Literature DB >> 30038052

CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Robert R McWilliams1, Eric D Wieben2,3, Kari G Chaffee4, Samuel O Antwi5, Leon Raskin6, Olufunmilayo I Olopade7, Donghui Li8, W Edward Highsmith3, Gerardo Colon-Otero9, Lauren G Khanna10, Jennifer B Permuth11, Janet E Olson4, Harold Frucht10, Jeanine Genkinger12,13, Wei Zheng6, William J Blot6, Lang Wu6, Luciana L Almada14, Martin E Fernandez-Zapico14, Hugues Sicotte4, Katrina S Pedersen15, Gloria M Petersen4.   

Abstract

Background: Pathogenic germline mutations in the CDKN2A tumor suppressor gene are rare and associated with highly penetrant familial melanoma and pancreatic cancer in non-Hispanic whites (NHW). To date, the prevalence and impact of CDKN2A rare coding variants (RCV) in racial minority groups remain poorly characterized. We examined the role of CDKN2A RCVs on the risk of pancreatic cancer among minority subjects.
Methods: We sequenced CDKN2A in 220 African American (AA) pancreatic cancer cases, 900 noncancer AA controls, and 183 Nigerian controls. RCV frequencies were determined for each group and compared with that of 1,537 NHW patients with pancreatic cancer. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for both a case-case comparison of RCV frequencies in AAs versus NHWs, and case-control comparison between AA cases versus noncancer AA controls plus Nigerian controls. Smaller sets of Hispanic and Native American cases and controls also were sequenced.
Results: One novel missense RCV and one novel frameshift RCV were found among AA patients: 400G>A and 258_278del. RCV carrier status was associated with increased risk of pancreatic cancer among AA cases (11/220; OR, 3.3; 95% CI, 1.5-7.1; P = 0.004) compared with AA and Nigerian controls (17/1,083). Further, AA cases had higher frequency of RCVs: 5.0% (OR, 13.4; 95% CI, 4.9-36.7; P < 0.001) compared with NHW cases (0.4%).Conclusions: CDKN2A RCVs are more common in AA than in NHW patients with pancreatic cancer and associated with moderately increased pancreatic cancer risk among AAs.Impact: RCVs in CDKN2A are frequent in AAs and are associated with risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 27(11); 1364-70. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30038052      PMCID: PMC6214745          DOI: 10.1158/1055-9965.EPI-17-1065

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  64 in total

1.  Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations.

Authors:  Sarah E Flanagan; Ann-Marie Patch; Sian Ellard
Journal:  Genet Test Mol Biomarkers       Date:  2010-08

2.  Studying cancer in minorities: a look at the numbers.

Authors:  Sara H Olson; Tracy M Layne; Jennifer A Simon; Emmy Ludwig; Eileen O'Reilly; Peter J Allen; Robert C Kurtz
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

3.  Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.

Authors:  E Yakobson; P Shemesh; E Azizi; E Winkler; N Lassam; D Hogg; S Brookes; G Peters; M Lotem; A Zlotogorski; M Landau; M Safro; R Shafir; E Friedman; H Peretz
Journal:  Eur J Hum Genet       Date:  2000-08       Impact factor: 4.246

4.  p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.

Authors:  K Milde-Langosch; E Ocon; G Becker; T Löning
Journal:  Int J Cancer       Date:  1998-02-20       Impact factor: 7.396

5.  Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma.

Authors:  Robert R McWilliams; Kari G Rabe; Curtis Olswold; Mariza De Andrade; Gloria M Petersen
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

6.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

8.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.

Authors:  J Lukas; D Parry; L Aagaard; D J Mann; J Bartkova; M Strauss; G Peters; J Bartek
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

9.  p16INK4 gene mutations are relatively frequent in ampullary carcinomas.

Authors:  Y Imai; N Tsurutani; H Oda; Y Nakatsuru; T Inoue; T Ishikawa
Journal:  Jpn J Cancer Res       Date:  1997-10

10.  Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.

Authors:  Femke A de Snoo; D Timothy Bishop; Wilma Bergman; Inge van Leeuwen; Clasine van der Drift; Frans A van Nieuwpoort; Coby J Out-Luiting; Hans F Vasen; Jeanet A C ter Huurne; Rune R Frants; Rein Willemze; Martijn H Breuning; Nelleke A Gruis
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

View more
  10 in total

Review 1.  Diversity and Inclusion in Pancreatic Cancer Clinical Trials.

Authors:  Kelly M Herremans; Andrea N Riner; Robert A Winn; Jose G Trevino
Journal:  Gastroenterology       Date:  2021-08-17       Impact factor: 22.682

Review 2.  The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.

Authors:  Hirokazu Kimura; Alison P Klein; Ralph H Hruban; Nicholas J Roberts
Journal:  Pancreas       Date:  2021-09-01       Impact factor: 3.243

3.  Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.

Authors:  Lisa Mirabello; Bin Zhu; Roelof Koster; Eric Karlins; Michael Dean; Meredith Yeager; Matthew Gianferante; Logan G Spector; Lindsay M Morton; Danielle Karyadi; Leslie L Robison; Gregory T Armstrong; Smita Bhatia; Lei Song; Nathan Pankratz; Maisa Pinheiro; Julie M Gastier-Foster; Richard Gorlick; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Ana Patino-Garcia; Fernando Lecanda; Miriam Gutierrez-Jimeno; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; Adrienne M Flanagan; Roberto Tirabosco; Maria Fernanda Amary; Nilgün Kurucu; Inci Ergurhan Ilhan; Mandy L Ballinger; David M Thomas; Donald A Barkauskas; Gerardo Mejia-Baltodano; Patricia Valverde; Belynda D Hicks; Bin Zhu; Mingyi Wang; Amy A Hutchinson; Margaret Tucker; Joshua Sampson; Maria T Landi; Neal D Freedman; Susan Gapstur; Brian Carter; Robert N Hoover; Stephen J Chanock; Sharon A Savage
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

4.  A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.

Authors:  Isaac P Horn; David L Marks; Amanda N Koenig; Tara L Hogenson; Luciana L Almada; Lauren E Goldstein; Paola A Romecin Duran; Renzo Vera; Anne M Vrabel; Gaofeng Cui; Kari G Rabe; William R Bamlet; Georges Mer; Hugues Sicotte; Cheng Zhang; Hu Li; Gloria M Petersen; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2021-04-03       Impact factor: 5.157

5.  Evaluation of the target genes of arsenic trioxide in pancreatic cancer by bioinformatics analysis.

Authors:  Cong-Ya Zhou; Liu-Yun Gong; Rong Liao; Ning-Na Weng; Yao-Yue Feng; Yi-Ping Dong; Hong Zhu; Ya-Qin Zhao; Yuan-Yuan Zhang; Qing Zhu; Su-Xia Han
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967

6.  Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.

Authors:  Hirokazu Kimura; Raymond M Paranal; Neha Nanda; Laura D Wood; James R Eshleman; Ralph H Hruban; Michael G Goggins; Alison P Klein; Nicholas J Roberts
Journal:  Elife       Date:  2022-01-10       Impact factor: 8.713

Review 7.  Modifiable and Non-Modifiable Risk Factors for the Development of Non-Hereditary Pancreatic Cancer.

Authors:  Marek Olakowski; Łukasz Bułdak
Journal:  Medicina (Kaunas)       Date:  2022-07-22       Impact factor: 2.948

8.  A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.

Authors:  Julie Earl; Cristina Galindo-Pumariño; Jessica Encinas; Emma Barreto; Maria E Castillo; Vanessa Pachón; Reyes Ferreiro; Mercedes Rodríguez-Garrote; Silvia González-Martínez; Teresa Ramon Y Cajal; Luis Robles Diaz; Isabel Chirivella-Gonzalez; Montse Rodriguez; Eva Martínez de Castro; David García-Seisdedos; Gloria Muñoz; Juan Manuel Rosa Rosa; Mirari Marquez; Nuría Malats; Alfredo Carrato
Journal:  EBioMedicine       Date:  2020-02-27       Impact factor: 8.143

9.  A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer.

Authors:  Esteban Astiazaran-Symonds; Alisa M Goldstein
Journal:  J Gastroenterol       Date:  2021-07-13       Impact factor: 6.772

10.  Authorship Patterns in Cancer Genomics Publications Across Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  JCO Glob Oncol       Date:  2021-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.